Journal of Cancer Research and Therapeutics · 2019 · 36 citations · 29 references
Life SciencesCancer BiologyOncologyGene ExpressionMolecular OncologyNeuroimmunologyCytokine BiologyCytokine TherapyCytokine-based TherapyInflammatory SignalingCell Growth RegulationCytokine Signaling In CancerCytokine Signaling In TumorsPrimary Brain NeoplasmsQuantitative Polymerase Chain ReactionReal-time Polymerase Chain Reaction (Pcr)Real-time Polymerase Chain Reaction Assays
OBJECTIVE: Glioma is one of the leading causes of death worldwide with high incidence, recurrence, and mortality. Interleukin-10 (IL-10) is a cytokine with dual function in many types of tumors. Although IL-10 is overexpressed and promotes tumor progression in human primary brain tumor, the mechanisms are largely unknown. MATERIALS AND METHODS: Glioma cells were treated with different dosages of IL-10. The cell growth was detected by CCK-8, and the invasion was measured by Transwell. The relative expression of messenger RNAs was detected by quantitative real-time polymerase chain reaction. RESULTS: We found that IL-10 treatment significantly enhanced glioma cell growth and invasion. Moreover, KPNA2 was significantly upregulated after treatment with IL-10. By performing knockdown experiments, we found that the glioma cell growth and invasion were significantly declined. CONCLUSIONS: The results indicated that knockdown of KPNA2 significantly inhibited the growth and invasion of glioma cells. Moreover, IL-10 promotes glioma progression via upregulation of KPNA2. This study will be of important significance and provides a potential target for treatment of patients with glioma.
29
Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis
Yibing Yang, Xinya Gao, Maolei Zhang et al. · JNCI Journal of the National Cancer Institute · 2017 · 1.2K citations · Full text
CGCG clinical practice guidelines for the management of adult diffuse gliomas
Tao Jiang, Ying Mao, Wenbin Ma et al. · Cancer Letters · 2016 · 650 citations · Full text
Medicine, Neurosurgery, Oncology +17